Skip to main content

MIT Corporate Relations

MIT Corporate Relations
MIT Logo
  • Events
  • STEX25
  • Startups
  • opportunities
  • MIT ILP
  • Sign-In
  • Register Your Startup
  • Search
STEX Home
  • Events
    • Corporates
    • Event Videos
    • Startups
  • STEX25
    • Featured
    • Videos
  • Startups
    • Search
    • News
  • opportunities
  • MIT ILP
User Menu and Search
  • Sign-In
  • Register Your Startup
STEX Home
Toggle menu
  • Sign-in
  • Register your startup
  • Events
    • Corporates
    • Event Videos
    • Startups
  • STEX25
    • Featured
    • Videos
  • Startups
    • Search
    • News
  • opportunities
  • MIT ILP

Search Results


Filter Results
Staff

Filter Results

Narrow your search results
  • News (7)
  • Videos (34)
  • Events (3)
  • Startup Opportunities (55)
  • Startups
  • Founders
Please sign-in to see the full search results
116 search results found
  • AI Driven Bloodless Blood Tests: GPx

    January 24, 2025 | Startup Exchange Video | Duration: 7:47

    AI Driven Bloodless Blood Tests
    Sean (Shunsuke) Matsuoka, Co-Founder & COO, GPx
    GPx: https://gpx.ai/

    In an aging society, the number of heart failure patients is increasing, making the prevention of readmissions and reduction of medical costs critical issues. Remote monitoring using invasive implantable devices has proven effective in reducing heart failure readmissions, but its use remains limited.

    To address this, GPx has developed an algorithm that non-invasively predicts signs of heart failure exacerbation. This algorithm was created using clinical trial data from monitoring 245 heart failure patients over 6 months to a year at eight facilities, including the Mayo Clinic in the U.S. The algorithm links digital 
    biomarker data with vital blood tests (NT-proBNP and creatinine) to achieve high-precision prediction and early medical intervention.

    Additionally, with a grant of 1.2 billion yen provided through AMED, we are collaborating with the National Cerebral and Cardiovascular Center (Dr. Chisato Izumi) to conduct a clinical trial involving 400 patients starting April 2025. The trial will be conducted at the National Cerebral and Cardiovascular Center, Kyoto University, Kobe University, and Kochi University.

    Furthermore, at this year's MIT Japan Conference, we will unveil a groundbreaking point-of-care (POC) potassium testing device for the first time. At the conference, we aim to explore the feasibility of applying our technology to other conditions (such as kidney failure, pulmonary arterial hypertension, and cardio-oncology) and to assess the potential for providing algorithm-based services for heart failure patients within Japan.

  • Kebotix, Inc.

    Cambridge, MA
    Software
    Kebotix uses artificial intelligence and robotics towards the discovery, synthesis, and formulation of advanced materials and specialty chemicals.
    Kebotix logo
  • Uncountable Inc.

    San Francisco, CA
    Technology
    Uncountable is a leading Unified Laboratory Informatics platform designed specifically for global enterprise R&D laboratories. Our cloud-native solution centralizes and integrates dispersed data sets into a unified knowledge base, offering powerful visualization tools and predictive analytics that... More
    uncountable_color
  • Past Deadline: Oct 18, 2019

    P&G Signal Accelerator Innovation Brief Call for Startup Submissions

    meeting

    Procter & Gamble is looking for new approaches and technologies that can help them to address key business challenges/opportunities. The following innovation brief(s) will provide a high-level overview of specific business goals and needs, as well as a high-level overview of what they are looking for in a solution.

  • DeepCure Inc.

    Boston, MA
    Biotechnology
    DeepCure develops disruptive Artificial Intelligence technology to revolutionize pharmaceutical development. The pharma industry is undoubtedly one of the world's largest, with worldwide revenues topping one trillion US dollars. However, its effectiveness is in question, as the exponentially... More
    Keywords:
    Artificial Intelligence, Deep Learning, Drug discovery, drug development, Biotechnology, Generative Drug Design, AI Driven Lead Optimization, Lead Discovery, Computational Chemistry, Beyond State-of-Art Machine Learning
  • Past Deadline: Sep 29, 2019

    P&G Signal Accelerator Innovation Brief Call for Startup Submissions

    meeting

    Procter & Gamble is looking for new approaches and technologies that can help them to address key business challenges/opportunities. The following innovation brief(s) will provide a high-level overview of specific business goals and needs, as well as a high-level overview of what they are looking for in a solution.

  • Past Deadline: Mar 20, 2020

    Procter & Gamble Innovation Brief Call for Startup Submissions

    meeting

    Procter & Gamble is looking for new approaches and technologies that can help them to address their broad range of sustainability challenges/opportunities. The following innovation brief(s) will provide a high-level overview of specific business goals and needs, as well as a high-level overview of what they are looking for in a solution. 

  • OPT Industries, Inc.

    Medford, MA
    Materials
    OPT Industries combines computational design, additive manufacturing, and polymer science to manufacture metamaterials with micron-scale precision. Through our photolithography-based 3D-printing technology, we bring new product concepts and rapidly scalable production capacity to globally... More
    Keywords:
    additive manufacturing, metamaterials, packaging materials
    Opt Industries logo
  • Kytopen Corporation

    Cambridge, MA
    Biotechnology
    Kytopen is developing platforms to accelerate the discovery and manufacturing of next-generation cell & gene therapies. The Flowfect technology offers a scalable, non-viral solution to deliver genetic payloads to cells in order to augment their functionality. The technology also enables continuous... More
    Keywords:
    Flowfect(R), Non-Viral, Gene Editing, CRISPR delivery, Continuous Processing, cell therapy, Genome Engineering, CAR T-cells, Engineered TCR T-cells
    Kytopen
  • Ling-Synthetic Biology

    Synthetic Biology Workshop 2017 - Industry View - Why We Care About New Materials

    September 12, 2017 | Startup Exchange Video | Duration: 10:27

    Vincent Ling, Senior Director, Materials and Innovation, Takeda 

Pagination

  • of 9
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next page
  • Events
    • Corporates
    • Event Videos
    • Startups
  • STEX25
    • Featured
    • Videos
  • Startups
    • Search
    • News
  • opportunities
  • MIT ILP
  • Twitter
  • YouTube
  • LinkedIn
Home

1 Main Street
12th Floor, E90-1201
Cambridge, MA 02142


Accessibility

Privacy Policy

617-253-2691
startupexchange@mit.edu

Office of Corporate Relations